VANCOUVER, BC / ACCESSWIRE / May 25, 2020 / Ovation Science Inc. (CSE:OVAT) (“Ovation” or the “Company”), is providing an update to its previous disclosures regarding its DermSafe® hand sanitizer product. This release provides updates to regulatory status, sales, manufacturing, and the science which supports DermSafe.
DermSafe hand sanitizing lotion provides a protective solution that is unique from other products on the market due to its patented polymer skin delivery technology Invisicare® and its use of chlorhexidine gluconate (CHG) as the active ingredient versus alcohol. DermSafe helps prevent the cross-contamination of bacteria and viruses between people and from contact with hard surfaces. CHG is a well established active ingredient as it has been used in hospitals worldwide for over 60 years in pre-surgical soaps as well as dental applications.
DermSafe Regulatory Approval
DermSafe Sales and Manufacturing
DermSafe® Science
DermSafe has undergone many independent studies on its effectiveness and other benefits. Although the Company has not tested DermSafe against the COVID19 virus, an envelope virus, several viral tests were carried out by an internationally recognized, independent laboratory plus US FDA compliant laboratories on other envelope viruses including H1N1, H5N1 and H3N2. Additionally, the Invisicare polymer was tested to show its ability to remain bound to the skin for extended periods of time. A list of these studies, all conducted at independent laboratories, are summarized below:
1. Tests conducted by independent lab, Retroscreen Virology Ltd., Center for Infectious Diseases Bart’s & The London Queen Mary’s School of Medicine and Dentistry, London, United Kingdom:
Evaluation of Antiviral Properties of a Product Using a Virucidal Suspension Assay:
Evaluation of Antiviral Properties of a Product Testing Virucidal Activity on Skin Tissue:
2. Test conducted by ATS Labs., Eagan, Minnesota (US FDA compliant / independent lab):
Evaluation of Antiviral Properties of a Product Using a Virucidal Suspension Assay:
3. Test conducted by Bioscience Laboratories, Inc., Bozeman, Montana (US FDA compliant / independent lab):
Evaluation of the Persistent Antimicrobial Efficacy on E.coli (Anti-Bacterial) of DermSafe at 2 and 4 Hours after Application (#90864-150 Oct/09):
4. Test conducted by California Skin Research Institute, San Diego, CA (US FDA compliant / independent lab):
Invisicare Persistence Study (#98-065 September/98):
For information about Ovation Science products visit https://ovationscience.com/products/.
To learn more about Ovation Science, please visit: www.ovationscience.com
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance that the Company’s DermSafe product will be licensed or approved for sale in Israel, Japan, Brazil, Columbia, Mexico, Kuwait or Greece and that if approval is obtained that it will result in sales in those countries. Although DermSafe has been tested against other envelope viruses there is no assurance that it will kill or be as effective against COVID-19. In addition there is no assurance the Company’s level of sales will continue or will not be negatively impacted by increased competition and recovery from the coronavirus pandemic. Other examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: strategies, potential sales, distribution and manufacturing of the Company’s product as well as its effectiveness against COVID-19, the Company’s ability to receive regulatory approval outside of Canada. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact:
FOR INVESTOR RELATIONS:
Dave Ryan: dave@ovationscience.com 604.283.0903 ext. 2
FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:
Doreen McMorran: doreen@ovationscience.com Phone: 604.283.0903 ext. 4
SOURCE: Ovation Science Inc.
View source version on accesswire.com:
https://www.accesswire.com/591335/Ovation-Science-Provides-Update-to-DermSafe-Status-Sales-and-Manufacturing
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a…
QINGDAO, China, July 12, 2024 /PRNewswire/ -- During the EURO 2024 tournament, the global home…
LAS VEGAS, July 12, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with…
Important Notice About a Privacy MatterSAN JUAN, PUERTO RICO / ACCESSWIRE / July 12, 2024…
HANGZHOU, China, July 12, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or…
HOUSTON, July 12, 2024 /PRNewswire/ -- Inhance Technologies welcomes the opportunity to engage with the…